- Home
- RARE vs HTO Comparison
RARE vs HTO Comparison
Compare RARE & HTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RARE | HTO |
|---|---|---|
| Founded | 2010 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Water Supply |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | RARE | HTO |
|---|---|---|
| Price | $21.26 | $58.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 3 |
| Target Price | ★ $66.32 | $60.00 |
| AVG Volume (30 Days) | ★ 2.0M | 510.1K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.12% |
| EPS Growth | ★ 7.31 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $673,000,000.00 | N/A |
| Revenue This Year | $13.40 | $9.74 |
| Revenue Next Year | $42.83 | $6.17 |
| P/E Ratio | ★ N/A | $17.19 |
| Revenue Growth | ★ 20.13 | N/A |
| 52 Week Low | $18.41 | $43.75 |
| 52 Week High | $40.54 | $58.45 |
Technical Indicators
Market Signals| Indicator | RARE | HTO |
|---|---|---|
| Relative Strength Index (RSI) | 37.40 | 67.49 |
| Support Level | $19.61 | $50.67 |
| Resistance Level | $25.46 | N/A |
| Average True Range (ATR) | 0.98 | 1.82 |
| MACD | 0.03 | 0.27 |
| Stochastic Oscillator | 39.06 | 97.29 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About HTO H2O America
H2O America is a national investor-owned network of local water and wastewater utilities united by one purpose: delivering clean, high-quality water to the communities it calls home. Across approximately 407,000 water and wastewater service connections, the company invests in critical infrastructure to strengthen the water supply for generations to come.